Eli Lilly has officially announced the acquisition of Orna Therapeutics, a biotech startup specializing in re-engineering immune cells directly inside the human body. The deal, valued at up to $2.4 billion, marks a significant step in Lilly’s strategy to expand its genetic medicine portfolio.
Breakthrough Circular RNA (oRNA) Technology Unlike traditional CAR-T therapies (ex vivo), which require extracting a patient’s cells for laboratory modification, Orna’s technology enables this process to occur within the patient’s body.
Orna’s platform utilizes circular RNA (oRNA) paired with lipid nanoparticles (LNPs). Compared to conventional linear mRNA, circular RNA is more robust, offering greater stability and prolonged protein expression. This allows for the “reprogramming” of a patient’s T-cells to identify and eliminate disease-causing targets without the need for complex, individualized factory manufacturing.
Focus on Autoimmune Diseases While CAR-T is often associated with oncology, Lilly is primarily leveraging Orna’s platform to address autoimmune conditions. Orna’s lead candidate, ORN-252, targets CD19 on malfunctioning B cells—the primary drivers of many inflammatory and autoimmune disorders.
Shifting to an in vivo (inside the body) model offers several key advantages:
-
Scalability: Eliminates the need for patient-specific manufacturing processes.
-
Accessibility: Reduces treatment wait times from weeks to a single, direct injection.
-
Reduced Toxicity: Minimizes the need for harsh pre-conditioning chemotherapy (lymphodepletion), which is often taxing for patients in traditional CAR-T protocols.
Deal Structure and Outlook The transaction includes an upfront cash payment plus additional payments contingent on reaching specific clinical development milestones. Through this acquisition, Lilly also gains access to Orna’s existing high-profile collaborations with partners like Merck & Co. and Vertex Pharmaceuticals, further strengthening its global pharmaceutical innovation ecosystem.